EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens



Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens



Clinical Infectious Diseases 39 Suppl 1: S25-S31



The etiology of bacteremia in febrile neutropenic patients in the past few decades has shifted from gram-negative to gram-positive organisms. Potential reasons include the use of indwelling catheters, local environmental conditions, and the administration of specific antibiotic agents, especially as prophylaxis. Other factors may emerge from new studies, such as the categorization of febrile neutropenic patients into groups at low risk and at high risk of developing serious complications, continuing changes in resistance in the community, the use of antibiotic-coated catheters, and future changes in cytotoxic chemotherapy or antineoplastic therapy. In addition, there has been a drift in susceptibility patterns, with resistance issues seen in the general population of hospitalized patients now emerging in febrile neutropenic patients, as well as some issues specific to these patients. These changes affect empirical therapy as it was practiced a decade ago. Among the most commonly used agents, cefepime and carbapenems continue to show the highest rates of in vitro susceptibility, providing coverage against most gram-positive and gram-negative organisms and reducing the need for glycopeptides. Older agents continue to show degradation of their effectiveness. Among Pseudomonas aeruginosa strains, susceptibility to all agents continues to decline.

(PDF emailed within 0-6 h: $19.90)

Accession: 011843550

Download citation: RISBibTeXText

PMID: 15250017

DOI: 10.1086/383048



Related references

Trends in spectrum and susceptibility patterns of pathogens causing bacteremia in pediatric febrile neutropenic oncologic patients. International Journal of Infectious Diseases 6(Supplement 2): 2S28-2S31, June, 2002

Serum bactericidal activity of meropenem and ceftazidime against septicemia pathogens isolated from febrile neutropenic cancer patients. Abstracts of the General Meeting of the American Society for Microbiology 94(0): 26, 1994

Impact of trimethoprim-sulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia. Antimicrobial Agents and ChemoTherapy 46(2): 594-597, 2002

Lactobacillus bacteremia in febrile neutropenic patients in a cancer hospital. Clinical Infectious Diseases 26(5): 1247-1248, 1998

Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Medical Oncology 26(1): 55-61, 2008

Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Annals of PharmacoTherapy 39(1): 32-38, 2004

Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?. Supportive Care in Cancer 19(7): 1001-1008, 2011

Association between antifungal prophylaxis and occurrence of bacteremia in febrile neutropenic cancer patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 380, 1997

Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. Journal of Infectious Diseases 162(4): 981-983, 1990

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clinical Infectious Diseases 32(11): 1532-1537, 2001

Staphylococcus aureus bacteremia and outcome of hickman catheter salvage in febrile neutropenic patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 298, 2002

Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies. International Journal of Infectious Diseases 14 Suppl 3(): E171-E175, 2011

Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. Journal of Antimicrobial ChemoTherapy 41 Suppl D: 57-64, 1998

A study of bacteremia in febrile neutropenic patients at a tertiary-care hospital with special reference to anaerobes. Medical Oncology 19(4): 267-272, 2003

Outcomes of Hickman catheter salvage in febrile neutropenic cancer patients with Staphylococcus aureus bacteremia. Infection Control and Hospital Epidemiology 24(12): 897-904, 2004